dihexa hgf c-met cancer risk

dihexa hgf c-met cancer risk (PNB-0408) | c-Met/HGFR Activator dihexa hgf c-met cancer risk

Name: dihexa hgf c-met cancer risk (PNB-0408) | c-Met/HGFR Activator dihexa hgf c-met cancer risk
Brand: ldesquadrias.com.br
SKU: 65685439692
Price: 22.44 USD
Availability: InStock
Rating: 4.7461 (26 reviews)

dihexa hgf c met cancer risk HGF c MET pathway in cancer: from molecular characterization to clinical evidence Targeted Inhibition of Hepatocyte Growth Hepatocyte Growth Factor c Met Signaling in Head and Neck Cancer and Implications for Treatment Correlation between hypoxia and HGF c MET expression in the management of pancreatic cancer ScienceDirect Targeting cancer associated fibroblast activated HGF c MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity ScienceDirect Downstream signalling and specific inhibition of c MET HGF pathway in small cell lung cancer: implications for tumour invasion British Journal of Cancer c MET: A Key Target in Cancer Therapy

SKU: 65685439692 · From ldesquadrias.com.br

4.7

USD22.44 USD47.44

Pay in 4 interest-free payments of $5.61 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 2 - Aug 7

Description

Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IB kinase activity